GeneQuine develops drugs that are based on gene therapy. The concept of gene therapy is to introduce genetic material into the patient’s own cells in the body. The cells produce then a therapeutic protein according to the template that the introduced genetic material (DNA) provides
GeneQuine is focused on the development of gene therapy agents for the treatment of osteoarthritis. Osteoarthritis is a degenerative joint disorder characterized by cartilage loss and inflammation. Patients affected by osteoarthritis experience joint pain as well as swelling and stiffness of the joints leading to limited joint functionality and impaired mobility. Osteoarthritis is the most common joint disorder with approximately 80 million people in the EU and the USA being currently affected. Moreover, osteoarthritis is also a major health problem in companion animals such as horses and dogs with approximately 1 million and 18 million patients respectively.